marked.bio

Company

PAQ Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

cetuximab 2

Trials

2 of 2 trials shown

  1. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    Recruiting Phase 1 PAQ Therapeutics Started 2025Primary completion 2028-10 NCT07300150

    PT0511cetuximab

    A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    KRAS G12CKRAS G12DColorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor

  2. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

    Recruiting Phase 1 PAQ Therapeutics Started 2024Primary completion 2026-12 NCT06797336

    PT0253Chemotherapy Combination 1Chemotherapy Combination 2Chemotherapy Combination 3cetuximab

    …rticipant has a pathologically documented, locally advanced or metastatic malignancy with KRAS p.G12D mutation identified through molecular testing using a Clinical Laboratory Improvement Ame…

    KRAS G12DSolid Tumor